Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
One in five deaths among low-income adults with advanced fibrosis could be averted if they had access to adequate food.
A companion study will look at liver biopsy results to confirm these findings from noninvasive tests.
Inadequate access to healthy food was also associated with a higher chance of developing liver fibrosis.
An elevated liver stiffness measurement was also independently linked to older age and higher body mass, among other factors.
This measurement also informed researchers about the risk of loss of liver function and death in people cured of hepatitis C.
What is the difference between a liver biopsy and a Fibroscan?
No significant links were found between liver stiffness prior to antiviral treatment and cirrhosis, liver cancer or transplants or death.
Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
Hepatitis C is one of the leading causes for cirrhosis, cancer and liver transplants. Here is what you need to know...
The regulatory agency requested further data to show whether its benefits outweigh its risks.
While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.